Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Erratum: Publisher Correction: Mathematical model of hemodynamic mechanisms and consequences of glomerular hypertension in diabetic mice.

Mahato HS, Ahlstrom C, Jansson-Löfmark R, Johansson U, Helmlinger G, Hallow KM.

NPJ Syst Biol Appl. 2019 Mar 4;5:9. doi: 10.1038/s41540-019-0081-8. eCollection 2019.

2.

The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone.

Bamberg K, William-Olsson L, Johansson U, Jansson-Löfmark R, Hartleib-Geschwindner J.

J Renin Angiotensin Aldosterone Syst. 2019 Jan-Mar;20(1):1470320319827449. doi: 10.1177/1470320319827449.

3.

Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection.

Granberg KL, Yuan ZQ, Lindmark B, Edman K, Kajanus J, Hogner A, Malmgren M, O'Mahony G, Nordqvist A, Lindberg J, Tångefjord S, Kossenjans M, Löfberg C, Brånalt J, Liu D, Selmi N, Nikitidis G, Nordberg P, Hayen A, Aagaard A, Hansson E, Hermansson M, Ivarsson I, Jansson-Löfmark R, Karlsson U, Johansson U, William-Olsson L, Hartleib-Geschwindner J, Bamberg K.

J Med Chem. 2019 Feb 14;62(3):1385-1406. doi: 10.1021/acs.jmedchem.8b01523. Epub 2019 Jan 30.

PMID:
30596500
4.

Mathematical model of hemodynamic mechanisms and consequences of glomerular hypertension in diabetic mice.

Mahato HS, Ahlstrom C, Jansson-Löfmark R, Johansson U, Helmlinger G, Hallow KM.

NPJ Syst Biol Appl. 2018 Dec 10;5:2. doi: 10.1038/s41540-018-0077-9. eCollection 2019. Erratum in: NPJ Syst Biol Appl. 2019 Mar 4;5:9.

5.

Corrigendum to 'Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development' Drug Discovery Today 23 (2018) 1733-1745.

Andersson S, Antonsson M, Elebring M, Jansson-Löfmark R, Weidolf L.

Drug Discov Today. 2018 Dec 7. pii: S1359-6446(18)30517-8. doi: 10.1016/j.drudis.2018.11.025. [Epub ahead of print] No abstract available.

PMID:
30529076
6.

Targeted delivery of antisense oligonucleotides to pancreatic β-cells.

Ämmälä C, Drury WJ 3rd, Knerr L, Ahlstedt I, Stillemark-Billton P, Wennberg-Huldt C, Andersson EM, Valeur E, Jansson-Löfmark R, Janzén D, Sundström L, Meuller J, Claesson J, Andersson P, Johansson C, Lee RG, Prakash TP, Seth PP, Monia BP, Andersson S.

Sci Adv. 2018 Oct 17;4(10):eaat3386. doi: 10.1126/sciadv.aat3386. eCollection 2018 Oct.

7.

Inferring Half-Lives at the Effect Site of Oligonucleotide Drugs.

Jansson-Löfmark R, Gennemark P.

Nucleic Acid Ther. 2018 Dec;28(6):319-325. doi: 10.1089/nat.2018.0739. Epub 2018 Oct 31.

PMID:
30328765
8.

Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development.

Andersson S, Antonsson M, Elebring M, Jansson-Löfmark R, Weidolf L.

Drug Discov Today. 2018 Oct;23(10):1733-1745. doi: 10.1016/j.drudis.2018.05.030. Epub 2018 May 28. Review. Erratum in: Drug Discov Today. 2018 Dec 7;:.

PMID:
29852223
9.

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.

Bamberg K, Johansson U, Edman K, William-Olsson L, Myhre S, Gunnarsson A, Geschwindner S, Aagaard A, Björnson Granqvist A, Jaisser F, Huang Y, Granberg KL, Jansson-Löfmark R, Hartleib-Geschwindner J.

PLoS One. 2018 Feb 23;13(2):e0193380. doi: 10.1371/journal.pone.0193380. eCollection 2018.

10.

Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.

Erlandsson F, Albayaty M, Chialda L, Ericsson H, Amilon C, Nelander K, Jansson-Löfmark R, Wernevik L, Kjaer M, Bamberg K, Hartleib-Geschwindner J.

Br J Clin Pharmacol. 2018 Jul;84(7):1486-1493. doi: 10.1111/bcp.13562. Epub 2018 Apr 22.

PMID:
29468715
11.

Evaluation of pharmacokinetic and pharmacodynamic profiles of liposomes for the cell type-specific delivery of small molecule drugs.

Dasa SSK, Suzuki R, Mugler E, Chen L, Jansson-Löfmark R, Michaëlsson E, Lindfors L, Klibanov AL, French BA, Kelly KA.

Nanomedicine. 2017 Nov;13(8):2565-2574. doi: 10.1016/j.nano.2017.07.005. Epub 2017 Jul 25.

12.

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.

Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, Jansson-Löfmark R, Naylor J, Rossi A, Bednarek MA, Bhagroo N, Salari H, Will S, Oldham S, Hansen G, Feigh M, Klein T, Grimsby J, Maguire S, Jermutus L, Rondinone CM, Coghlan MP.

Diabetes Obes Metab. 2016 Dec;18(12):1176-1190. doi: 10.1111/dom.12735. Epub 2016 Aug 15.

13.

Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.

Jansson-Löfmark R, Na-Bangchang K, Björkman S, Doua F, Ashton M.

Antimicrob Agents Chemother. 2015 Feb;59(2):1299-307. doi: 10.1128/AAC.04101-14. Epub 2014 Dec 15.

14.

A modeling approach for compounds affecting body composition.

Gennemark P, Jansson-Löfmark R, Hyberg G, Wigstrand M, Kakol-Palm D, Håkansson P, Hovdal D, Brodin P, Fritsch-Fredin M, Antonsson M, Ploj K, Gabrielsson J.

J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):651-67. doi: 10.1007/s10928-013-9337-x. Epub 2013 Oct 25.

PMID:
24158456
15.

Model-based drug discovery: implementation and impact.

Visser SA, Aurell M, Jones RD, Schuck VJ, Egnell AC, Peters SA, Brynne L, Yates JW, Jansson-Löfmark R, Tan B, Cooke M, Barry ST, Hughes A, Bredberg U.

Drug Discov Today. 2013 Aug;18(15-16):764-75. doi: 10.1016/j.drudis.2013.05.012. Epub 2013 May 29. Review.

PMID:
23726890
16.

Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat.

Johansson CC, Gennemark P, Artursson P, Äbelö A, Ashton M, Jansson-Löfmark R.

J Pharmacokinet Pharmacodyn. 2013 Feb;40(1):117-28. doi: 10.1007/s10928-012-9293-x. Epub 2013 Jan 10.

PMID:
23307171
17.

Feedback modeling of non-esterified fatty acids in rats after nicotinic acid infusions.

Ahlström C, Peletier LA, Jansson-Löfmark R, Gabrielsson J.

J Pharmacokinet Pharmacodyn. 2011 Feb;38(1):1-24. doi: 10.1007/s10928-010-9172-2. Epub 2010 Nov 4.

18.

Determination of eflornithine enantiomers in plasma by precolumn derivatization with o-phthalaldehyde-N-acetyl-L-cysteine and liquid chromatography with UV detection.

Jansson-Löfmark R, Römsing S, Albers E, Ashton M.

Biomed Chromatogr. 2010 Jul;24(7):768-73. doi: 10.1002/bmc.1361.

PMID:
20020417

Supplemental Content

Loading ...
Support Center